You are currently viewing a new version of our website. To view the old version click .

103 Results Found

  • Article
  • Open Access
1 Citations
2,088 Views
9 Pages

Prevalence of Cannabidiol (CBD) Use Among Patients Taking Medications with Known Drug–Drug Interactions: A Cross-Sectional Analysis

  • Hunter Geneau,
  • Michael Kovasala,
  • Grant Brown,
  • Simeon Holmes,
  • Olivia Hime,
  • Michael McNally,
  • Michael McFayden,
  • Kori Brewer and
  • G. Kirk Jones

2 November 2025

Introduction: Cannabidiol (CBD) is widely available over the counter for presumed medical and recreational purposes. Despite its non-psychoactive nature, CBD exhibits intrinsic pharmacological activity that may lead to potential adverse drug events (...

  • Article
  • Open Access
117 Views
5 Pages

Background: Errors in prescriptions are associated with adverse drug events. The aim of the study was to characterise prescribing errors in patients transferred from the emergency department (ED) to the inpatient ward. Methods: A prospective observat...

  • Article
  • Open Access
3 Citations
4,669 Views
14 Pages

Documentation of Drug-Related Problems with ICD-11: Application of the New WHO Code-Set to Clinical Routine Data

  • Wahram Andrikyan,
  • Lea Jung-Poppe,
  • Anna Altenbuchner,
  • Hagen Fabian Nicolaus,
  • Barbara Pfistermeister,
  • Harald Dormann,
  • Martin F. Fromm and
  • Renke Maas

31 December 2022

Drug-related problems (DRPs), i.e., adverse drug reactions (ADRs) and medication errors (MEs), constitute a serious threat to the patient’s safety. DRPs are often insufficiently captured by clinical routine documentation, and thus, they frequently re...

  • Review
  • Open Access
6 Citations
3,030 Views
13 Pages

28 November 2023

To overcome the epidemiological severity of cancer, developing effective treatments is urgently required. In response, immune checkpoint inhibitors (ICIs) have been revealed as a promising resolution for treatment-resistant cancers across the world....

  • Article
  • Open Access
2 Citations
3,670 Views
9 Pages

Signal Detection Study Focusing on Differences in the Drug Delivery System of Oral 5-Aminosalicylate for Inflammatory Bowel Disease Using the Japanese Pharmacovigilance Database

  • Yoshihiro Noguchi,
  • Shuji Yamashita,
  • Hirofumi Tamaki,
  • Arihiro Osanai,
  • Yoko Ino,
  • Tomoya Tachi,
  • Kazuhiro Iguchi and
  • Hitomi Teramachi

Although 5-Aminosalicylate (5-ASA) has been shown to act on the local mucosa, when 5-ASA is orally administered, most of it is absorbed in the upper gastrointestinal tract and does not reach the large intestine, where lesions are present. Therefore,...

  • Review
  • Open Access
48 Citations
8,345 Views
18 Pages

Anti-Alzheimer’s Molecules Derived from Marine Life: Understanding Molecular Mechanisms and Therapeutic Potential

  • Md. Tanvir Kabir,
  • Md. Sahab Uddin,
  • Philippe Jeandet,
  • Talha Bin Emran,
  • Saikat Mitra,
  • Ghadeer M. Albadrani,
  • Amany A. Sayed,
  • Mohamed M. Abdel-Daim and
  • Jesus Simal-Gandara

28 April 2021

Alzheimer’s disease (AD) is a devastating neurodegenerative disease and the most common cause of dementia. It has been confirmed that the pathological processes that intervene in AD development are linked with oxidative damage to neurons, neuroinflam...

  • Review
  • Open Access
54 Citations
11,071 Views
15 Pages

Drug interactions are a well-known cause of adverse drug events, and drug interaction databases can help the clinician to recognize and avoid such interactions and their adverse events. However, not every interaction leads to an adverse drug event. T...

  • Article
  • Open Access
1,391 Views
12 Pages

Causal Inference of Adverse Drug Events in Pulmonary Arterial Hypertension: A Pharmacovigilance Study

  • Hongmei Li,
  • Xiaojun He,
  • Cui Chen,
  • Qiao Ni,
  • Linghao Ni,
  • Jiawei Zhou and
  • Bin Peng

22 July 2025

Objective: Pulmonary arterial hypertension (PAH) is a progressive and life-threatening disease. Adverse events (AEs) related to its drug treatment seriously damaged the patient’s health. This study aims to clarify the causal relationship betwee...

  • Case Report
  • Open Access
3,588 Views
8 Pages

9 October 2019

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm constituting approximately 15% of newly diagnosed leukemia in adult patients. Development of tyrosine kinase inhibitors (TKIs) have dramatically improved outcomes in patients with chroni...

  • Article
  • Open Access
12 Citations
5,124 Views
17 Pages

Impact of Adverse Drug Reactions in Patients with End Stage Renal Disease in Greece

  • Marios Spanakis,
  • Marianna Roubedaki,
  • Ioannis Tzanakis,
  • Michail Zografakis-Sfakianakis,
  • Evridiki Patelarou and
  • Athina Patelarou

Background: Patients with end-stage renal disease (ESRD) require specialized therapeutic interventions. The decreased renal function that modulates the physiology and presence of comorbidities is often associated with variations in the pharmacologica...

  • Article
  • Open Access
3 Citations
2,052 Views
25 Pages

A comprehensive pharmacovigilance surveillance on antibacterials is lacking. This study aims to investigate safety signals of antibacterial-related adverse drug events (ADEs) with seriousness and to identify predictors of serious ADEs. This study inv...

  • Article
  • Open Access
3 Citations
2,579 Views
14 Pages

A Real-World Data Derived Pharmacovigilance Assessment on Drug-Induced Nephropathy: Implication on Gaps in Patient Care

  • Yujin Kim,
  • Chang-Young Choi,
  • Yongjun Sunwoo,
  • Chaerin Go,
  • Semi Kim,
  • Sae Hyun Eom,
  • Sooyoung Shin and
  • Yeo Jin Choi

31 December 2023

This retrospective cross-sectional study aims to investigate the prevalence and seriousness of drug-induced nephrotoxicity and to identify clinical predictors intensifying the seriousness of nephrotoxicity. Adverse drug events (ADEs) reported to the...

  • Article
  • Open Access
965 Views
13 Pages

Background: While adverse drug events (ADEs) are a major public health concern, data on the occurrence of lethal or fatal ADEs in Japan are limited. Therefore, this study aimed to elucidate the characteristics and reporting trends of lethal or fatal...

  • Article
  • Open Access
3 Citations
3,820 Views
20 Pages

Background: Adverse drug reactions (ADRs) refer to an unintended harmful reaction that occurs after the administration of a medication for therapeutic purposes, which is unrelated to the intended pharmacological action of the drug. In the United Stat...

  • Article
  • Open Access
7 Citations
4,310 Views
16 Pages

Reporting Antimicrobial-Related Adverse Drug Events in Jordan: An Analysis from the VigiBase Database

  • Nizar Mahmoud Mhaidat,
  • Sayer Al-Azzam,
  • Hayaa Abdallah Banat,
  • Jaber Mohammad Jaber,
  • Mohammad Araydah,
  • Osama Y. Alshogran and
  • Mamoon A. Aldeyab

This study aims to assess the reporting of antimicrobial-related adverse drug events (ADEs) in Jordan between 2003 and 2022. Data regarding the antimicrobial-related ADEs were extracted from the WHO’s global database (VigiBase) by the Rational...

  • Article
  • Open Access
3 Citations
2,150 Views
10 Pages

Shortcomings of Administrative Data to Derive Preventive Strategies for Inhospital Drug-Induced Acute Kidney Failure—Insights from Patient Record Analysis

  • Stefanie Amelung,
  • David Czock,
  • Markus Thalheimer,
  • Torsten Hoppe-Tichy,
  • Walter E. Haefeli and
  • Hanna M. Seidling

23 July 2022

Structured analyses of hospital administrative data may detect potentially preventable adverse drug events (ADE) and therefore are considered promising sources to prevent future harm and estimate cost savings. Whether results of these analyses indeed...

  • Article
  • Open Access
5 Citations
8,519 Views
13 Pages

Drug Safety During Breastfeeding: A Comparative Analysis of FDA Adverse Event Reports and LactMed®

  • Hülya Tezel Yalçın,
  • Nadir Yalçın,
  • Michael Ceulemans and
  • Karel Allegaert

9 December 2024

Background/Objectives: While breastfeeding is highly recommended, breastfed infants may be exposed to drugs by milk due to maternal pharmacotherapy, resulting in a risk of adverse drug events (ADE) or reactions (ADRs). The U.S. Food and Drug Administ...

  • Article
  • Open Access
3 Citations
2,605 Views
13 Pages

Real-World Data-Derived Pharmacovigilance on Drug-Induced Cognitive Impairment Utilizing a Nationwide Spontaneous Adverse Reporting System

  • Yongjun Sunwoo,
  • Sae Hyun Eom,
  • Ji Seong Yun,
  • Yujin Kim,
  • Jeongmin Lee,
  • Soo Hyeon Lee,
  • Sooyoung Shin and
  • Yeo Jin Choi

23 June 2024

Background and Objectives: Despite high incidences of cognitive impairment with aging, evidence on the prevalence and the seriousness of drug-induced cognitive impairment is limited. This study aims to evaluate the prevalence and the severity of drug...

  • Article
  • Open Access
17 Citations
7,288 Views
19 Pages

Which Adverse Events and Which Drugs Are Implicated in Drug-Related Hospital Admissions? A Systematic Review and Meta-Analysis

  • Annette Haerdtlein,
  • Elisabeth Debold,
  • Marietta Rottenkolber,
  • Anna Maria Boehmer,
  • Yvonne Marina Pudritz,
  • Faiza Shahid,
  • Jochen Gensichen and
  • Tobias Dreischulte

7 February 2023

Adverse drug events (ADEs) and adverse drug reactions (ADRs) are leading causes of iatrogenic injury, which can result in emergency department (ED) visits or admissions to inpatient wards. The aim of this systematic review and meta-analysis was to pr...

  • Article
  • Open Access
8 Citations
3,106 Views
13 Pages

Antibacterial drug exposure (ADE) is a well-known potential risk factor for Clostridium difficile infection (CDI), but it remains controversial which certain antibacterial drugs are associated with the highest risk of CDI occurrence. To summarize CDI...

  • Case Report
  • Open Access
4 Citations
4,164 Views
8 Pages

Pharmacogenomics and Drug-Induced Phenoconversion Informed Medication Safety Review in the Management of Pain Control and Quality of Life: A Case Report

  • Selina Muhn,
  • Nishita Shah Amin,
  • Chandni Bardolia,
  • Nicole Del Toro-Pagán,
  • Katie Pizzolato,
  • David Thacker,
  • Jacques Turgeon,
  • Crystal Tomaino and
  • Veronique Michaud

15 June 2022

Utilizing pharmacogenomics (PGx) and integrating drug-induced phenoconversion to guide opioid therapies could improve the treatment response and decrease the occurrence of adverse drug events. Genetics contribute to the interindividual differences in...

  • Article
  • Open Access
2 Citations
1,149 Views
25 Pages

Backgrounds/Objectives: This study aims to comprehensively characterize the prevalence and severity of antiepileptic drug (AED)-induced adverse drug events (ADEs) and to identify predictors strongly associated with serious adverse events (SAEs) in bo...

  • Article
  • Open Access
2 Citations
7,526 Views
17 Pages

Background: Proton pump inhibitors (PPIs) are widely used for gastric acid suppression, yet their efficacy and safety in neonates and infants remain unclear. While esomeprazole is the only Food and Drug Administration (FDA)-approved PPI for neonates...

  • Article
  • Open Access
2 Citations
2,010 Views
16 Pages

22 May 2025

Background/Objectives: Bradycardia, an uncharacteristically low heart rate below 60 bpm, is a commonly reported adverse drug event (ADE) in individuals administered dexmedetomidine for sedation. Dexmedetomidine is frequently used as a sedative and an...

  • Systematic Review
  • Open Access
2 Citations
3,251 Views
13 Pages

Placebo-Related Adverse Events in Rheumatoid Arthritis

  • Ratna Shree Sharma,
  • Johannes Pallua and
  • Michael Schirmer

14 February 2022

Prospective, double-blind, randomized, placebo-controlled studies are considered to provide the highest quality of interventional evidence. This meta-analysis summarizes the frequencies of adverse events according to the Medical Dictionary for Regula...

  • Article
  • Open Access
6 Citations
3,628 Views
23 Pages

Drug Related Problems among Older Inpatients at a Tertiary Care Setting

  • Porrawee Pramotesiri,
  • Krongtong Putthipokin and
  • Sirasa Ruangritchankul

13 March 2024

Background: Older persons are more likely to have multiple chronic diseases, leading to the simultaneous use of many medications. This situation results in increased drug-related problems (DRPs), which are the causes of adverse health outcomes. There...

  • Article
  • Open Access
4 Citations
2,575 Views
9 Pages

17 July 2023

Background—Direct-to-consumer (DTC) sequential aligners promote “teeth straightening” at a low cost and with added patient convenience. DTC sequential aligners have risen in popularity among the general public and sparked debate amo...

  • Article
  • Open Access
18 Citations
6,174 Views
19 Pages

Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed Drugs to Drug Regimens of Frail Older Adults with Polypharmacy

  • Sweilem B. Al Rihani,
  • Matt K. Smith,
  • Ravil Bikmetov,
  • Malavika Deodhar,
  • Pamela Dow,
  • Jacques Turgeon and
  • Veronique Michaud

10 August 2020

Determination of the risk–benefit ratio associated with the use of novel coronavirus disease 2019 (COVID-19) repurposed drugs in older adults with polypharmacy is mandatory. Our objective was to develop and validate a strategy to assess risk for adve...

  • Article
  • Open Access
6 Citations
5,606 Views
11 Pages

Prevalence of Adverse Drug Events in Severely Obese Adults and Associated Factors: Clinical Trial Baseline Results

  • Ana Carolina Figueiredo Modesto,
  • Erika Aparecida Silveira,
  • Annelisa Silva e Alves de Carvalho Santos,
  • Ana Paula dos Santos Rodrigues,
  • Dione Marçal Lima,
  • Mércia Pandolfo Provin and
  • Rita Goreti Amaral

23 September 2020

Drugs are the most widely used therapeutic tool for treatment of diseases. However, misuse can lead to an adverse drug event (ADE) in susceptible individuals such as those that are severely obese. This study aimed to describe the frequency of ADEs, t...

  • Article
  • Open Access
1,725 Views
20 Pages

17 June 2025

Backgrounds and Objectives: This study aims to characterize the prevalence and severity of antidepressant-associated adverse drug events (ADEs) and to identify predictors strongly associated with serious adverse events (SAEs). Materials and Methods:...

  • Review
  • Open Access
11 Citations
4,801 Views
19 Pages

27 April 2025

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by epidermal barrier dysfunction and immune dysregulation, with interleukin (IL)-4, IL-13, and IL-31 recognized as key mediators. Prurigo nodularis (PN) is another chronic in...

  • Article
  • Open Access
1 Citations
3,425 Views
14 Pages

Anticholinergic Burden and Safety Outcomes in Older Patients with Chronic Hepatitis C: A Retrospective Cohort Study

  • Patricia Amoros-Reboredo,
  • Dolors Soy,
  • Marta Hernandez-Hernandez,
  • Sabela Lens and
  • Conxita Mestres

Aim: Older patients with chronic hepatitis C infection starting direct-acting antivirals (DAAs) are frequently prescribed multiple medications that may be categorized as inappropriate. Anticholinergic burden has been shown to be a predictor of advers...

  • Article
  • Open Access
6 Citations
2,546 Views
9 Pages

Treatment with Methotrexate in Infants and Toddlers with Atopic Dermatitis: A Retrospective Multi-Center Study

  • Jen A. Barak Levitt,
  • Sima Alemi,
  • Ayelet Ollech,
  • Shiran Reiss-Huss,
  • Mohammad Sah,
  • Yael Renert-Yuval,
  • Rivka Friedland,
  • Shoshana Greenberger and
  • Eran Cohen Barak

20 August 2023

Atopic dermatitis (AD) is a chronic inflammatory skin disease affecting up to 20% of children. Methotrexate (MTX) is used off-label as a systemic treatment for AD patients unresponsive to topical therapies, but limited data exist regarding its safety...

  • Feature Paper
  • Article
  • Open Access
10 Citations
3,536 Views
12 Pages

Drug Survival of Upadacitinib and Predicting Factors of Discontinuation in Adult Patients Affected by Moderate-to-Severe Atopic Dermatitis: An Italian Multicenter Analysis

  • Elena Pezzolo,
  • Michela Ortoncelli,
  • Silvia Mariel Ferrucci,
  • Mario Bruno Guanti,
  • Donatella Schena,
  • Maddalena Napolitano,
  • Mariateresa Rossi,
  • Caterina Foti,
  • Domenico D’Amico and
  • Giuseppe Fabrizio Amoruso
  • + 11 authors

18 January 2024

Background: Limited real-world data are available on upadacitinib drug survival in patients with atopic dermatitis (AD). Objectives: To investigate upadacitinib drug survival, and the reasons and predictors of drug discontinuation in AD patients. Met...

  • Article
  • Open Access
13 Citations
4,607 Views
11 Pages

Liver Injury with Nintedanib: A Pharmacovigilance–Pharmacokinetic Appraisal

  • Emanuel Raschi,
  • Michele Fusaroli,
  • Milo Gatti,
  • Paolo Caraceni,
  • Elisabetta Poluzzi and
  • Fabrizio De Ponti

Drug-induced liver injury (DILI) with nintedanib has emerged as an adverse event of special interest in premarketing clinical trials. We characterized DILI with nintedanib in the real world and explored the underlying pharmacological basis. First, we...

  • Article
  • Open Access
13 Citations
8,076 Views
18 Pages

Analysis of Factors Associated with Hiccups Using the FAERS Database

  • Ryuichiro Hosoya,
  • Reiko Ishii-Nozawa,
  • Kota Kurosaki and
  • Yoshihiro Uesawa

24 December 2021

In this study, we used the large number of cases in the FDA adverse-event reporting system (FAERS) database to investigate risk factors for drug-induced hiccups and to explore the relationship between hiccups and gender. From 11,810,863 adverse drug...

  • Review
  • Open Access
34 Citations
6,355 Views
19 Pages

7 April 2021

Janus kinase (JAK) inhibitors are promising treatments for atopic dermatitis (AD). The aim of this study was to assess the efficacy and safety of JAK inhibitors for AD treatment via the “Grading of Recommendations Assessment, Development, and Evaluat...

  • Review
  • Open Access
229 Citations
57,064 Views
14 Pages

Cannabidiol (CBD) is ubiquitous in state-based medical cannabis programs and consumer products for complementary health or recreational use. CBD has intrinsic pharmacologic effects and associated adverse drug events (ADEs) along with the potential fo...

  • Article
  • Open Access
5 Citations
640 Views
11 Pages

Background: Adjuvant treatment options have become the standard therapy for stage III and IV resectable cutaneous melanoma. Two recent studies led to the registration of dabrafenib and trametinib as targeted therapies for BRAF-mutated melanoma, and o...

  • Article
  • Open Access
11 Citations
3,412 Views
18 Pages

Risk of Hospitalization for Adverse Drug Events in Women and Men: A Post Hoc Analysis of an Active Pharmacovigilance Study in Italian Emergency Departments

  • Giada Crescioli,
  • Ennio Boscia,
  • Alessandra Bettiol,
  • Silvia Pagani,
  • Giulia Spada,
  • Giuditta Violetta Vighi,
  • Roberto Bonaiuti,
  • Mauro Venegoni,
  • Giuseppe Danilo Vighi and
  • Alfredo Vannacci
  • + 2 authors

This post hoc analysis of an Italian active pharmacovigilance study describes pharmacological differences of ADEs leading to emergency department (ED) visits and hospitalization in women and men. During the study period (January 2007–December 2018),...

  • Article
  • Open Access
8 Citations
2,497 Views
14 Pages

Prioritisation of Adverse Drug Events Leading to Hospital Admission and Occurring during Hospitalisation: A RAND Survey

  • Annette Haerdtlein,
  • Anna Maria Boehmer,
  • Katharina Karsten Dafonte,
  • Marietta Rottenkolber,
  • Ulrich Jaehde and
  • Tobias Dreischulte

22 July 2022

(1) Adverse drug events (ADEs) are a common cause of emergency department visits and occur frequently during hospitalisation. Instruments that facilitate the detection of the most relevant ADEs could lead to a more targeted and efficient use of limit...

  • Article
  • Open Access
7 Citations
2,876 Views
16 Pages

Frequency, Characteristics, and Predictive Factors of Adverse Drug Events in an Adult Emergency Department according to Age: A Cross-Sectional Study

  • Laura Lohan,
  • Grégory Marin,
  • Marie Faucanie,
  • Marion Laureau,
  • Damien Perier,
  • Véronique Pinzani,
  • Isabelle Giraud,
  • Maxime Villiet,
  • Mustapha Sebbane and
  • Ariane Sultan
  • + 1 author

27 September 2022

Adverse drug events (ADEs) are a major public health concern, given their consequences in terms of morbi-mortality and associated healthcare costs. Many studies have focused on the elderly, who are considered particularly vulnerable in this respect....

  • Article
  • Open Access
20 Citations
4,722 Views
11 Pages

Adverse Drug Events in Patients with Dementia and Neuropsychiatric/Behavioral, and Psychological Symptoms, a One-Year Prospective Study

  • Marta H. Hernández,
  • Conxita Mestres,
  • Pilar Modamio,
  • Jaume Junyent,
  • Lluís Costa-Tutusaus,
  • Cecilia F. Lastra and
  • Eduardo L. Mariño

Older people usually present with adverse drug events (ADEs) with nonspecific symptoms such as cognitive decline, recurrent falls, reduced mobility, and/or major deterioration. The aims of this study were to assess the ADEs of patients with dementia...

  • Case Report
  • Open Access
2 Citations
4,751 Views
7 Pages

Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report

  • Collin J. Amundson,
  • Robert Knight,
  • Georgina M. Ybarra,
  • Jacques Turgeon and
  • Jennifer M. Bingham

17 March 2022

Polypharmacy of psychotropic medications predisposes older adults to adverse drug events (ADEs). One contributing factor is inhibition of metabolic pathways between substrates (competitive inhibition) or between substrates and inhibitors of the same...

  • Article
  • Open Access
10 Citations
3,044 Views
10 Pages

Early Assessment of Efficacy and Safety of Biologics in Pediatric Allergic Diseases: Preliminary Results from a Prospective Real-World Study

  • Lucia Caminiti,
  • Francesca Galletta,
  • Simone Foti Randazzese,
  • Paolo Barraco,
  • Stefano Passanisi,
  • Antonella Gambadauro,
  • Giuseppe Crisafulli,
  • Mariella Valenzise and
  • Sara Manti

28 January 2024

Background: Despite the increasing interest in biologics for the management of allergic diseases, sparse real-world data are still available in the pediatric population. This study aimed to evaluate the early real-life efficacy and safety of omalizum...

  • Review
  • Open Access
16 Citations
22,460 Views
11 Pages

7 February 2022

Diabetes is a common and complex disease affecting multiple organ systems throughout the body. With a consensus in care guidelines emphasizing the importance of glycemic control in determining the disease progression, people with diabetes worldwide h...

  • Article
  • Open Access
17 Citations
4,314 Views
18 Pages

Topical Delivery of Ketorolac Tromethamine via Cataplasm for Inflammatory Pain Therapy

  • Zhiyuan Hou,
  • Qiang Wen,
  • Wenhu Zhou,
  • Peng Yan,
  • Hailong Zhang and
  • Jinsong Ding

Nonsteroidal anti-inflammatory drugs (NSAIDs) have been widely used in the treatment of inflammatory pain, such as in osteoarthritis. Ketorolac tromethamine is considered to be an NSAID with strong anti-inflammatory and analgesic potency, however, tr...

  • Review
  • Open Access
8 Citations
10,633 Views
15 Pages

Adverse drug reactions (ADRs) are frequent and represent a significant healthcare burden. ADRs are a potentially avoidable contributor to excess unscheduled hospital admissions, higher morbidity, mortality, and healthcare costs. The objective of this...

  • Article
  • Open Access
257 Views
19 Pages

Dexmedetomidine is a commonly used sedative because it has minimal adverse effects on respiratory function. Nevertheless, its cardiovascular safety profile, particularly bradycardia risk and drug–drug interactions (DDIs), remains incompletely u...

of 3